OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.

Autor:	Rivkin AZ; David Geffen School of Medicine, UCLA, Los Angeles, California., Ogilvie P; Skin Concept, Munich, Germany., Dayan S; DeNova Research, Chicago, Illinois., Yoelin SG; Medical Associates Inc., Newport Beach, California., Weichman BM; Peloton Advantage, Parsippany, New Jersey., Garcia JK; Health Economics Outcomes Research, Allergan plc, Irvine, California.
Jazyk:	angličtina
Zdroj:	Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] [Dermatol Surg] 2020 Jan; Vol. 46 (1), pp. 50-60.
DOI:	10.1097/DSS.0000000000001883
Abstrakt:	Background: Patient-reported outcomes are increasingly recognized as important measures of treatment benefit. Objective: To evaluate subject-reported satisfaction and impact outcomes with onabotulinumtoxinA treatment in neurotoxin-naive adults with forehead lines (FHL), glabellar lines (GL), and crow's feet lines (CFL). Methods: This Phase 3 study randomized 787 subjects to onabotulinumtoxinA 64 U (FHL 20 U, GL 20 U, and CFL 24 U), 40 U (FHL 20 U, GL 20 U, and CFL placebo), or placebo in double-blind Period 1. Subjects could receive up to 2 additional 64 U treatments in open-label Period 2. Patient-reported outcomes were assessed using the validated Facial Line Satisfaction Questionnaire (FLSQ) and 11-item Facial Line Outcomes (FLO-11) Questionnaire. Results: The proportion of subjects mostly or very satisfied was significantly greater with onabotulinumtoxinA 64 U and 40 U versus placebo (87.9% and 81.4% vs 3.2%; p < .0001). Responder rates on FLSQ Impact Domain, FLO-11 Items 1, 4, 5, and total score were significantly greater with onabotulinumtoxinA versus placebo on Day 30 (p < .0001). Responder rates favoring onabotulinumtoxinA in Period 1 were maintained with repeated onabotulinumtoxinA 64 U treatment in Period 2. Conclusion: OnabotulinumtoxinA treatment was associated with high subject satisfaction and significant improvements in appearance-related psychological and emotional impacts.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu